Sat, Jan 31, 2015, 7:44 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Omeros Corporation (OMER) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • bull_ridr bull_ridr Nov 17, 2009 1:04 PM Flag

    11/19 Conference Call

    Why would NIH perform an investigation if there were no potential improprieties??? CFO's rarely file lawsuits against companies - especially those about to IPO - makes one wonder about what's really going on there at OMER.

    Could be "where there is smoke, there is fire"???

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • OR maybe, just maybe, Omeros was right about this CFO and got rid of him despite the pending IPO. Both Deutsche Bank and Canaccord initiated coverage of Omeros today with price targets of $15 and $13, respectively. Reading their coverages they seem to have little concern about Omeros' "failure to execute". Go figure.

      • 2 Replies to Gaudisso
      • From the Deutsche Bank buy recommendation yesterday:

        Outlook

        Omeros is an emerging pharmaceutical company focused on developing novel therapeutics
        for treating inflammation and CNS disorders. The company’s PharmacoSurgery platform is an
        innovative concept for either improving surgical ease or patient outcomes or both. The
        PharmacoSurgery product candidates that Omeros is currently developing are proprietary
        low-dose combinations of anti-inflammatory agents and other drugs. Local delivery of these
        products can potentially mitigate surgical trauma, reduce related pain and inflammation and
        help accelerate patient recovery. Omeros is targeting a theoretical $7 billion+ worldwide
        sales opportunity with its lead product candidate OMS103HP, which is currently in Phase 3
        for use in arthroscopic surgery, as well as OMS302 for ophthalmic surgery and OMS201 for
        urologic surgeries. Management is pursuing 505b2 filings for these products—typically a
        faster, less onerous application process—as they are composed of already-approved active
        ingredients. If successfully developed and approved, we believe that surgeons will be
        motivated to utilize Omeros’ products as they potentially improve clinical outcomes without
        changing current standard surgical workflows. Overall, we currently model a $1 billion+ peak
        potential for Omeros’ three PharmacoSurgery product candidates, assuming they are all
        approved by the FDA.

        Beyond the PharmacoSurgery platform, Omeros possesses a suite of preclinical programs
        focused on developing novel therapeutics for CNS indications such as schizophrenia,
        Parkinson’s disease, and substance addictions. In addition, the company has a G-protein
        coupled receptor (GPCR) platform technology with the capacity to characterize previously
        unknown GPCRs in a high-throughput manner, which could ultimately yield novel
        pharmaceuticals. While we have not ascribed any value to these programs in our valuation
        analysis (see “Valuation” section for more details), the GPCR program, as well as the
        company’s preclinical CNS programs could potentially be compelling for a large
        pharmaceutical partner and yield relatively lucrative collaboration(s) for Omeros. Hence,
        based on the company’s broad and diverse clinical pipeline, as well as its very attractive
        valuation, we rate Omeros’ shares Buy.

      • Both Deutsche Bank and Canaccord initiated coverage of Omeros today with price targets of $15 and $13, respectively. Reading their coverages they seem to have little concern about Omeros' "failure to execute". Go figure.

        Not sure if it still works this way but isn't the lead investment bank and the top row bankers on the tombstone, lined up right up front to publish positive reports. But, oh no, not DucheBank, the lead, they wouldn't efer pull the Moody's, S&P, and Fitch would rate junk AAA for the company paying them ... How much in fees did DoucheBank pocket on this gig?

 
OMER
22.24-1.1200(-4.79%)Jan 30 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Boot Barn Holdings, Inc.
NYSEFri, Jan 30, 2015 4:02 PM EST
Amazon.com Inc.
NASDAQFri, Jan 30, 2015 4:00 PM EST